Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Anti-angiogenic effect of tamo...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
Show other versions (1)
Bibliographic Details
Main Authors:
Mele, T
,
Generali, D
,
Fox, S
,
Brizzi, M
,
Bersiga, A
,
Milani, M
,
Allevi, G
,
Bonardi, S
,
Aguggini, S
,
Volante, M
,
Dogliotti, L
,
Bottini, A
,
Harris, A
,
Berruti, A
Format:
Journal article
Published:
2010
Holdings
Description
Other Versions (1)
Similar Items
Staff View
Description
Summary:
Similar Items
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
by: Mele, T, et al.
Published: (2010)
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
by: Fox, S, et al.
Published: (2011)
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
by: Fox, S, et al.
Published: (2011)
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
by: Generali, D, et al.
Published: (2009)
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
by: Generali, D, et al.
Published: (2009)